Medpace/MEDP

0.88%
-
1D1W1MYTD1YMAX

About Medpace

Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.

Ticker

MEDP

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

August Troendle

Employees

5,800

Headquarters

Cincinnati, United States

Medpace Metrics

BasicAdvanced
US$12B
Market cap
40.08
P/E ratio
US$9.81
EPS
1.39
Beta
-
Dividend rate
US$12B
1.39135
US$421.00
US$197.39
249K
0.779
38.338
19.58%
61.31%
46.2%
40.076
6.208
18.105
25.744
25.57%
24.32%
26.76%
32.18%

What the Analysts think about Medpace

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
13.06% upside
High US$480.00
Low US$395.00
US$396.79
Current price
US$448.60
Average price target

Medpace Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
20.05% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
US$511M
2.53%
Net income
US$103M
31.07%
Profit margin
20.05%
27.79%

Medpace Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 29.82%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
US$1.93
US$2.22
US$2.46
US$3.20
-
Expected
US$1.91
US$2.05
US$2.22
US$2.47
US$2.54
Surprise
0.79%
8.5%
10.71%
29.82%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Medpace stock?

Medpace (MEDP) has a market cap of $12B as of May 20, 2024.

What is the P/E ratio for Medpace stock?

The price to earnings (P/E) ratio for Medpace (MEDP) stock is 40.08 as of May 20, 2024.

Does Medpace stock pay dividends?

No, Medpace (MEDP) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Medpace dividend payment date?

Medpace (MEDP) stock does not pay dividends to its shareholders.

What is the beta indicator for Medpace?

Medpace (MEDP) has a beta rating of 1.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Medpace stock price target?

The target price for Medpace (MEDP) stock is $448.6, which is 12.93% above the current price of $397.25. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Medpace stock

Buy or sell Medpace stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing